Moomoo AI 已提取核心信息
On January 8, 2024, Johnson & Johnson announced its definitive agreement to acquire Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company, for approximately $2.0 billion in an all-cash transaction. The acquisition aims to strengthen Johnson & Johnson's oncology portfolio with Ambrx's advanced antibody drug conjugates (ADCs) and proprietary technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer, and the company also has other candidates in development for various cancer types. The transaction, which is expected to close in the first half of 2024, is subject to Ambrx shareholder approval and regulatory clearances. Upon completion, Ambrx will no longer be listed on the NASDAQ Global Select Market. This move reflects Johnson & Johnson's commitment to oncology innovation and the development of targeted therapeutics.
On January 8, 2024, Johnson & Johnson announced its definitive agreement to acquire Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company, for approximately $2.0 billion in an all-cash transaction. The acquisition aims to strengthen Johnson & Johnson's oncology portfolio with Ambrx's advanced antibody drug conjugates (ADCs) and proprietary technology platform. Ambrx's lead product candidate, ARX517, targets metastatic castration-resistant prostate cancer, and the company also has other candidates in development for various cancer types. The transaction, which is expected to close in the first half of 2024, is subject to Ambrx shareholder approval and regulatory clearances. Upon completion, Ambrx will no longer be listed on the NASDAQ Global Select Market. This move reflects Johnson & Johnson's commitment to oncology innovation and the development of targeted therapeutics.
2024年1月8日，强生公司宣布以约20亿美元的全现金交易收购临床阶段生物制药公司Ambrx Biopharma, Inc. 的最终协议。此次收购旨在通过Ambrx的先进抗体药物偶联物（ADC）和专有技术平台加强强生公司的肿瘤产品组合。Ambrx的主要候选产品 ARX517 针对转移性去势抗性前列腺癌，该公司还针对各种癌症类型开发了其他候选产品。该交易预计将于2024年上半年完成，尚待Ambrx股东批准和监管许可。完成后，Ambrx将不再在纳斯达克全球精选市场上市。此举反映了强生对肿瘤学创新和靶向疗法开发的承诺。
2024年1月8日，强生公司宣布以约20亿美元的全现金交易收购临床阶段生物制药公司Ambrx Biopharma, Inc. 的最终协议。此次收购旨在通过Ambrx的先进抗体药物偶联物（ADC）和专有技术平台加强强生公司的肿瘤产品组合。Ambrx的主要候选产品 ARX517 针对转移性去势抗性前列腺癌，该公司还针对各种癌症类型开发了其他候选产品。该交易预计将于2024年上半年完成，尚待Ambrx股东批准和监管许可。完成后，Ambrx将不再在纳斯达克全球精选市场上市。此举反映了强生对肿瘤学创新和靶向疗法开发的承诺。
有用
没用